The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
The Indian Council of Medical Research (ICMR), intends to enter into non-exclusive agreements with companies
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
Subscribe To Our Newsletter & Stay Updated
